Analyst Ratings for Ultragenyx Pharma (RARE)
RARE Rating Summary
RARE Price Target Summary
- Highest: $96.00 (Cantor Fitzgerald)
- Lowest: $25.00 (Goldman Sachs)
- Average: $56.17
* Over Last 12-Mos
Overall Rating:
BUY
Rating Trend:
Avg. $ Target:
$56.17 (+91.8%)
* Over Last 12-Mos
Rating Score: 8.1 / 10
Percentile Rank: 84%
Avg. $ Target:
$56.17 (+91.8%)
* Over Last 12-Mos
Rating Score: 8.1 / 10
Percentile Rank: 84%
| Date | Firm | Analyst | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 3/24/2026 | Goldman Sachs | Salveen Richter | Downgrade | Neutral (Buy) |
25.00 (61.00) |
19.87 (29.28) |
47.36% | Details |
| 10/20/2025 | Wells Fargo » Updated 5/6/2026 |
Ben Burnett | New Coverage | Overweight (N/A) |
47.00 (45.00) |
32.63 (29.28) |
-10.27% | Details |
 |
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
|
||||||||
